Skip to main content

PERSPECTIVE article

Front. Oncol.
Sec. Molecular and Cellular Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1387444
This article is part of the Research Topic Molecular Mechanisms and Immunotherapeutic Targets in Nanomedicine-based Cancer Therapy View all 5 articles

Targeting RNA N6-methyladenosine modification--a novel therapeutic target for HER2-positive gastric cancer

Provisionally accepted
Xiaoman Zeng Xiaoman Zeng *Wu Li Wu Li *Xiaowei Tian Xiaowei Tian *Lijun Jia Lijun Jia *
  • First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China

The final, formatted version of the article will be published soon.

    Gastric cancer is one of the most common cancers and is considered the 5 th most frequent occurring cancer worldwide. It has gained great attention from the clinicians and researchers because of high mortality rate. It is generally treated with chemotherapy, radiotherapy, and surgery. Recently, additional treatment options including immunotherapy and targeted therapy and immunotherapy have been developed. However, poor prognosis, limited survival rate of patients, and drug resistance to treatment remain critical problems. To improve treatment options or to overcome the bottleneck of treatment, identification of diagnostic and prognostic markers, determining the most effective therapeutic options, and uncovering the molecular regulations associated with treatment strategies are required. In this regard n 6 -methyladenosine (m6A) regulation is considered important. This reversible modification plays a crucial role in progression, development and treatment of HER2-positive gastric cancer. Here, we discuss the role of m6A modification in HER2-positive gastric cancer progression through collecting related studies at present. We further discuss the association of m6A modification with therapeutic efficacy in HER2-positive gastric cancer and list some examples. We conclude that modification of m6A can be a new strategy for improving the prognosis and survival rate of HER2-positive gastric cancer patients.

    Keywords: HER2-positive gastric cancer, n 6 -methyladenosine modification (m6A), Glycolysis regulation, therapeutic efficacy, Survival Rate

    Received: 17 Feb 2024; Accepted: 06 May 2024.

    Copyright: © 2024 Zeng, Li, Tian and Jia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xiaoman Zeng, First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China
    Wu Li, First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China
    Xiaowei Tian, First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China
    Lijun Jia, First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.